Literature DB >> 26426782

Bone morphogenetic protein receptor type II and inflammation are bringing old concepts into the new pulmonary arterial hypertension world.

Frédéric Perros1,2,3, Sébastien Bonnet3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26426782     DOI： 10.1164/rccm.201506-1115ED

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN： 1073-449X            Impact factor:   21.405


× No keyword cloud information.
  3 in total

Review 1.  Transcription factors, transcriptional coregulators, and epigenetic modulation in the control of pulmonary vascular cell phenotype: therapeutic implications for pulmonary hypertension (2015 Grover Conference series).

Authors:  Soni S Pullamsetti; Frédéric Perros; Prakash Chelladurai; Jason Yuan; Kurt Stenmark
Journal:  Pulm Circ       Date:  2016-12       Impact factor: 3.017

2.  Rescuing BMPR2-driven endothelial dysfunction in PAH: a novel treatment strategy for the future?

Authors:  Rozenn Quarck; Fréderic Perros
Journal:  Stem Cell Investig       Date:  2017-06-14

Review 3.  DNA Damage and Pulmonary Hypertension.

Authors:  Benoît Ranchoux; Jolyane Meloche; Roxane Paulin; Olivier Boucherat; Steeve Provencher; Sébastien Bonnet
Journal:  Int J Mol Sci       Date:  2016-06-22       Impact factor: 5.923
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.